The Generic Drug Market: Price Wars and Quality Challenges

In today’s market, companies must first secure market share and then focus on reducing overall costs through optimized production processes and lower operating expenses. Some argue that by maintaining a robust product line and using generic drugs to offset fixed costs and depreciation, companies can still sustain profitability.

Experts have highlighted the significance of low-cost specialty drugs with smaller annual usage volumes, such as Sugammadex Sodium Injection—developed by Merck and first launched in Europe in 2008. It entered the Chinese market in 2017 and once had global annual sales nearing 10 billion yuan.

As the domestic first generic of Sugammadex was introduced in 2022, prices plummeted from the “thousands” to the “hundreds” range. By the 10th procurement round, prices dropped further to just 8.7 yuan per vial. Despite this, industry insiders believe that the product’s market potential is unlikely to attract new competitors, resulting in a loss of market vitality.

Public concerns focus on whether low prices compromise quality. While industry professionals assert that low prices do not equate to low quality, they acknowledge that quality risks are inherent. Even within the pharmaceutical sector, practitioners prefer innovative drugs or products from reputable domestic manufacturers when economic conditions allow.

Generic drugs are essential for reducing costs and improving accessibility. They are significantly cheaper than innovator drugs because they bypass the expensive R&D phase. Through reverse engineering, generics replicate the active ingredients of innovator drugs and establish equivalent pharmaceutical quality and bioavailability standards.

A GMP audit expert described two scenarios for generic drug production:

1. “Learning the soul,” where generics achieve efficacy parity with the original drugs through rigorous quality controls and process optimization.
2. “Learning the form,” where generics mimic the original without delivering the same therapeutic effect.

Despite differences, generics are vital to making treatments affordable and accessible. However, the pressure of centralized procurement has forced many companies to adopt extreme cost-saving measures, risking quality. A balance between profitability and stringent quality control is necessary to ensure sustainability in the generic drug industry.

Policymakers must recognize these realities and create practical, industry-aligned regulations to encourage innovation while ensuring fair profitability for manufacturers.